Celgene Company Profile (NASDAQ:CELG)

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
Capitalization:
  • Market Cap: $91.18 billion
  • Outstanding Shares: 780,824,000
Average Prices:
  • 50 Day Moving Avg: $121.62
  • 200 Day Moving Avg: $119.73
  • 52 Week Range: $94.42 - $127.64
P/E:
  • Trailing P/E Ratio: 43.85
  • Foreward P/E Ratio: 13.26
  • P/E Growth: 0.77
Sales & Book Value:
  • Annual Revenue: $11.68 billion
  • Price / Sales: 7.81
  • Book Value: $9.79 per share
  • Price / Book: 11.93
Profitability:
  • EBIDTA: $4.11 billion
  • Net Margins: 17.80%
  • Return on Equity: 77.95%
  • Return on Assets: 16.00%
Debt:
  • Debt-to-Equity Ratio: 2.44%
  • Current Ratio: 3.61%
  • Quick Ratio: 3.42%
Misc:
  • Average Volume: 3.52 million shs.
  • Beta: 1.74
  • Short Ratio: 2
 

Frequently Asked Questions for Celgene (NASDAQ:CELG)

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) announced its earnings results on Thursday, April, 27th. The company reported $1.68 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. Celgene had a return on equity of 77.95% and a net margin of 17.80%. The company's quarterly revenue was up 17.8% compared to the same quarter last year. During the same period last year, the firm posted $1.32 EPS. View Celgene's Earnings History.

When will Celgene make its next earnings announcement?

Celgene is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.

Where is Celgene's stock going? Where will Celgene's stock price be in 2017?

25 brokerages have issued 1 year price targets for Celgene's shares. Their forecasts range from $98.00 to $162.00. On average, they expect Celgene's stock price to reach $139.59 in the next year. View Analyst Ratings for Celgene.

What are analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • 1. Cann analysts commented, "Celgene unexpectedly reported that Teva submitted an ANDA for Pomalyst, which it intends to defend against. Based on an analysis of Celgene’s patents for Pomalyst, we found that patent lives extend out to 2031. However, Celgene’s documents indicate the date is 2024. We believe this is because Celgene thinks there is an important patent expiring on this date." (4/4/2017)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Revlimid continued to outperform on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Fourth-quarter results were disappointing but the company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (3/9/2017)
  • 3. Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
  • 4. Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene stock?

Celgene's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.87%), Vanguard Group Inc. (6.65%), State Street Corp (4.16%), Jennison Associates LLC (1.70%), FMR LLC (1.52%) and Bank of New York Mellon Corp (1.30%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Thomas O Daniel. View Institutional Ownership Trends for Celgene.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Winslow Capital Management LLC, Parametric Portfolio Associates LLC, Renaissance Technologies LLC, Janus Capital Management LLC, Marshall Wace LLP and TCW Group Inc.. Company insiders that have sold Celgene stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of Montreal Can, Investec Asset Management LTD, OppenheimerFunds Inc., Wellington Management Group LLP, State Street Corp and Pioneer Investment Management Inc.. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of Celgene stock can currently be purchased for approximately $116.78.


MarketBeat Community Rating for Celgene (NASDAQ CELG)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  1,461 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  1,785
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene (NASDAQ:CELG) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 19 Buy Ratings
Consensus Rating:Buy (Score: 2.72)
Consensus Price Target: $139.59 (19.53% upside)

Analysts' Ratings History for Celgene (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017BTIG ResearchReiterated RatingBuy$138.00LowView Rating Details
5/24/2017JPMorgan Chase & Co.Reiterated RatingBuyLowView Rating Details
5/22/2017Cantor FitzgeraldSet Price TargetBuy$160.00LowView Rating Details
5/22/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
5/22/2017Credit Suisse Group AGSet Price TargetBuy$148.00LowView Rating Details
5/23/2017BMO Capital MarketsReiterated RatingOutperform$152.00MediumView Rating Details
5/22/2017Robert W. BairdReiterated RatingOutperform$162.00LowView Rating Details
5/17/2017Goldman Sachs Group IncReiterated RatingSell$93.00 -> $98.00LowView Rating Details
5/13/2017Jefferies Group LLCSet Price TargetBuy$154.00LowView Rating Details
5/5/2017ArgusDowngradeBuy -> Hold$123.91 -> $124.46MediumView Rating Details
4/27/2017CannReiterated RatingBuyLowView Rating Details
4/23/2017Barclays PLCReiterated RatingEqual Weight$120.00 -> $125.00LowView Rating Details
4/5/2017Oppenheimer Holdings Inc.Reiterated RatingOutperform$148.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
3/8/2017Cowen and CompanyReiterated RatingOutperform$150.00LowView Rating Details
2/19/2017MizuhoSet Price TargetBuy$130.00N/AView Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00N/AView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
12/4/2016Royal Bank of CanadaReiterated RatingOutperformN/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/20/2016Stifel NicolausSet Price TargetBuy$138.00N/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
9/29/2016Citigroup IncBoost Price TargetBuy$124.00 -> $127.00N/AView Rating Details
9/16/2016Bank of America CorpReiterated RatingBuy$128.00N/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
5/25/2016William BlairReiterated RatingOutperformN/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
4/28/2016SunTrust Banks, Inc.Reiterated RatingBuy$145.00 -> $147.00N/AView Rating Details
1/22/2016Wells Fargo & CoReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00N/AView Rating Details
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00N/AView Rating Details
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Celgene (NASDAQ:CELG)
Earnings by Quarter for Celgene (NASDAQ:CELG)
Earnings History by Quarter for Celgene (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.68
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20171$1.63$1.63$1.63
Q3 20171$1.77$1.77$1.77
Q4 20171$1.83$1.83$1.83
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene (NASDAQ:CELG)
Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 77.68%
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celgene (NASDAQ:CELG)
Latest Headlines for Celgene (NASDAQ:CELG)
Source:
DateHeadline
fool.com logoBetter Buy: Celgene Corporation vs. Bristol-Myers Squibb
www.fool.com - May 28 at 7:28 AM
americanbankingnews.com logoCelgene Co. (CELG) Receives "Outperform" Rating from BMO Capital Markets
www.americanbankingnews.com - May 27 at 11:52 PM
finance.yahoo.com logoI Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug
finance.yahoo.com - May 25 at 5:39 PM
americanbankingnews.com logoCelgene's (CELG) "Buy" Rating Reiterated at JPMorgan Chase & Co.
www.americanbankingnews.com - May 24 at 4:32 PM
americanbankingnews.com logoCelgene's (CELG) "Buy" Rating Reiterated at BTIG Research
www.americanbankingnews.com - May 24 at 4:32 PM
americanbankingnews.com logoCelgene Co. (CELG) Given a $148.00 Price Target by Credit Suisse Group AG Analysts
www.americanbankingnews.com - May 23 at 9:20 PM
americanbankingnews.com logoCelgene Co. (CELG) PT Set at $156.00 by Canaccord Genuity
www.americanbankingnews.com - May 23 at 8:04 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "$160.00" Price Target for Celgene Co. (CELG)
www.americanbankingnews.com - May 23 at 8:04 PM
finance.yahoo.com logoWill Novartis' MS Drug Stomp Celgene's Before It Even Hits The Market?
finance.yahoo.com - May 22 at 4:08 PM
americanbankingnews.com logoRobert W. Baird Reaffirms "Outperform" Rating for Celgene Co. (CELG)
www.americanbankingnews.com - May 22 at 2:00 PM
finance.yahoo.com logoCelgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
finance.yahoo.com - May 22 at 12:42 PM
finance.yahoo.com logoCelgene reports positive results in trial of multiple sclerosis treatment
finance.yahoo.com - May 22 at 12:42 PM
fool.com logoWhy Long-Term Investors Should Prefer Celgene Over Biogen
www.fool.com - May 21 at 9:12 AM
finance.yahoo.com logoTop 5 Biotech Stocks for 2017
finance.yahoo.com - May 19 at 8:49 AM
nasdaq.com logoAgios to Present Updated Clinical Data from PKR Activator AG-348 ... - Nasdaq
www.nasdaq.com - May 18 at 4:10 PM
feeds.benzinga.com logoAgios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
feeds.benzinga.com - May 18 at 7:33 AM
americanbankingnews.com logoCelgene Co. (CELG) Upgraded by Vetr Inc. to Strong-Buy
www.americanbankingnews.com - May 18 at 12:21 AM
finance.yahoo.com logoCelgene leukemia drug extends survival in early stage trial
finance.yahoo.com - May 17 at 9:20 PM
finance.yahoo.com logoBroad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)
finance.yahoo.com - May 17 at 9:20 PM
americanbankingnews.com logoCelgene Co. (CELG) Receives "Sell" Rating from Goldman Sachs Group Inc
www.americanbankingnews.com - May 17 at 2:50 PM
prnewswire.com logoNovartis' Cosentyx Takes the Wind Out of Stelara's Sails in Psoriatic Arthritis Market
www.prnewswire.com - May 16 at 9:20 PM
finance.yahoo.com logoCelgene's (CELG) Revlimid Looks Solid on Label Expansion
finance.yahoo.com - May 16 at 9:20 PM
seekingalpha.com logoCelgene Sales And Pipeline Keeping Pace With Expectations
seekingalpha.com - May 16 at 4:18 PM
bizjournals.com logoDragonfly Therapeutics Completes New Investment Round
www.bizjournals.com - May 15 at 12:21 PM
finance.yahoo.com logo3 Post-Earnings Biotech Buys
finance.yahoo.com - May 14 at 4:19 PM
seekingalpha.com logoEvotec AG's (EVOTF) CEO Werner Lanthaler on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 4:13 PM
nasdaq.com logoInvestec Asset Management LTD Buys Alphabet Inc, Celgene Corp, Microsoft Corp, Sells Activision ...
www.nasdaq.com - May 13 at 4:13 PM
americanbankingnews.com logoCelgene Co. (CELG) Lowered to "Buy" at Vetr Inc.
www.americanbankingnews.com - May 12 at 12:40 AM
finance.yahoo.com logoONCYF: FDA Grants Fast Track Authority
finance.yahoo.com - May 11 at 4:51 PM
seekingalpha.com logoBristol-Myers Squibb: A Deep Dive Finds Some Pearls
seekingalpha.com - May 10 at 4:24 PM
americanbankingnews.com logoCelgene Target of Unusually High Options Trading (CELG)
www.americanbankingnews.com - May 10 at 7:10 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Celgene and Kite Pharma
finance.yahoo.com - May 9 at 8:21 AM
americanbankingnews.com logoCelgene Co. (CELG) Upgraded to Strong-Buy by Vetr Inc.
www.americanbankingnews.com - May 9 at 12:18 AM
finance.yahoo.com logo[$$] Funding Snapshot: Aadi Bioscience Raises $23 Million Series A
finance.yahoo.com - May 8 at 9:10 PM
finance.yahoo.com logo​Aadi Bioscience gets $23 million funding
finance.yahoo.com - May 8 at 9:09 PM
finance.yahoo.com logoCelgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : May 5, 2017
finance.yahoo.com - May 6 at 2:28 AM
finance.yahoo.com logoHas Celgene Become Vulnerable To 'Revenue Concentration Risk'?
finance.yahoo.com - May 6 at 2:28 AM
finance.yahoo.com logoCelgene Stock Falls Following Argus Downgrade
finance.yahoo.com - May 6 at 2:28 AM
finance.yahoo.com logoCelgene: Too Much of a Good Thing?
finance.yahoo.com - May 6 at 2:28 AM
finance.yahoo.com logoDoes Celgene Have Too May Eggs In One Drug Basket?
finance.yahoo.com - May 5 at 9:27 PM
fool.com logoA Strong Case for Buying Celgene
www.fool.com - May 5 at 4:21 PM
fool.com logoJuno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration
www.fool.com - May 5 at 11:52 AM
americanbankingnews.com logoArgus Downgrades Celgene Co. (CELG) to Hold
www.americanbankingnews.com - May 5 at 11:16 AM
americanbankingnews.com logoCelgene Co. (CELG) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 5 at 10:14 AM
marketwatch.com logo10-Q: AGIOS PHARMACEUTICALS INC
www.marketwatch.com - May 4 at 9:23 PM
americanbankingnews.com logoInsider Selling: Celgene Co. (CELG) Director Sells 9,250 Shares of Stock
www.americanbankingnews.com - May 2 at 9:24 PM
americanbankingnews.com logoCelgene (CELG) Receives Daily Media Impact Score of 0.22
www.americanbankingnews.com - May 2 at 7:56 PM
fool.com logoCelgene Corporation: The Bear Case From a Bull
www.fool.com - May 2 at 8:47 AM
seekingalpha.com logoBiotech Forum Daily Digest: Earnings Season Commences - Spotlight On Agios Pharmaceuticals
seekingalpha.com - May 1 at 4:12 PM
finance.yahoo.com logoCelgene Corp. :CELG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017
finance.yahoo.com - May 1 at 4:12 PM

Social

Chart

Celgene (CELG) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff